AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reiterated by stock analysts at J P Morgan Chase & Co in a report issued on Thursday, May 11th.

Other equities analysts have also recently issued reports about the company. Deutsche Bank AG restated a “buy” rating and set a GBX 6,000 ($75.90) target price on shares of AstraZeneca plc in a report on Wednesday, January 18th. Morgan Stanley set a GBX 5,600 ($70.84) target price on AstraZeneca plc and gave the company a “buy” rating in a report on Wednesday, January 18th. Jefferies Group LLC reiterated a “buy” rating and issued a GBX 5,400 ($68.31) price objective on shares of AstraZeneca plc in a research note on Friday, January 13th. Kepler Capital Markets reiterated a “buy” rating and issued a GBX 5,000 ($63.25) price objective on shares of AstraZeneca plc in a research note on Monday, January 23rd. Finally, Liberum Capital reiterated a “buy” rating and issued a GBX 5,200 ($65.78) price objective on shares of AstraZeneca plc in a research note on Tuesday, January 31st. Five investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. AstraZeneca plc currently has an average rating of “Hold” and an average target price of GBX 5,121.80 ($64.79).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Shares of AstraZeneca plc (AZN) opened at 5284.00 on Thursday. The company has a 50-day moving average of GBX 5,087.18 and a 200-day moving average of GBX 4,684.86. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00. The stock’s market capitalization is GBX 66.90 billion.

COPYRIGHT VIOLATION WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/06/17/astrazeneca-plc-azn-rating-reiterated-by-jpmorgan-chase-co-updated-updated-2-updated.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.